The clinical courses, including tumor stage at diagnosis, presence of brain metastasis, OS and RFS, are similar among lung adenocarcinoma patients with different KRAS mutation subtypes. Additionally, PD-L1 expression status appears to be independent of KRAS mutation subtypes. Of note, concurrent PD-L1 expression and G12C mutation is associated with particularly poorer prognosis. Further study is needed to see if PD1/PD-L1 block may improve outcome of this group of patients.
Luwei Tao, Jingxin Sun, Tarek Mekhail, Lingbin Meng, Yuan Du, Mark A. Socinski, Amanda Allen, Brenda L. Rzeszutko, Chung-Che Chang
